PT-141, known by its generic pharmaceutical name bremelanotide and its brand name Vyleesi, is the first and only FDA-approved non-hormonal treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women. Unlike phosphodiesterase inhibitors (Viagra, Cialis) that work peripherally through blood flow, PT-141 acts centrally in the brain through the melanocortin system — making it pharmacologically distinct from any other approved sexual health treatment.
PT-141 works by directly activating desire and arousal pathways in the central nervous system, which is why it's effective for conditions rooted in low desire rather than just physical performance.
What Is PT-141 (Bremelanotide)?
PT-141 is a cyclic heptapeptide derived from Melanotan II. When Melanotan II was being studied for its tanning effects, researchers noticed that test subjects reported unexpected increases in sexual desire and spontaneous erections. Follow-up research identified this as a melanocortin receptor effect, and PT-141 was developed as a more targeted compound for this specific application — retaining the sexual function benefits while reducing the tanning and other off-target effects.
PT-141 was approved by the FDA in June 2019 as Vyleesi (bremelanotide injection) for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women.
Mechanism of Action
Melanocortin Receptor 4 (MC4R) Agonism
PT-141's primary mechanism is agonism at melanocortin receptor 4 (MC4R) in the central nervous system, particularly in the hypothalamus and limbic system. MC4R activation in these regions directly modulates sexual desire, motivation, and arousal — not by increasing blood flow, but by activating desire at the neurological level.
MC4R is distinct from the tanning receptor (MC1R) and the cortisol-related receptor (MC2R), making PT-141 relatively selective for CNS effects at therapeutic doses.
Dopamine System Interaction
MC4R signaling interacts extensively with the mesolimbic dopamine system — the brain's reward pathway. PT-141 appears to potentiate dopamine signaling in circuits involved in motivation and desire, which likely contributes to its pro-sexual effects.
No Peripheral Vascular Mechanism
This is the key pharmacological distinction: PT-141 does not work by increasing nitric oxide or dilating blood vessels (the mechanism of PDE5 inhibitors). It works on desire and arousal at the brain level. This means it can be effective when the issue is low desire rather than erectile dysfunction or physical arousal problems.
MC1R Activity (Tanning)
At higher doses, PT-141 activates MC1R (the melanocortin tanning receptor), which is why its parent compound Melanotan II causes tanning. The approved Vyleesi dose minimizes but does not eliminate MC1R activity.
FDA Approval: Vyleesi
The FDA approved bremelanotide (Vyleesi) in 2019 specifically for acquired, generalized HSDD in premenopausal women. HSDD is characterized by low sexual desire that causes distress and is not explained by other medical conditions or medications.
The approval was based on two Phase 3 clinical trials (RECONNECT studies) showing that bremelanotide significantly improved desire and reduced distress related to sexual function compared to placebo.
Approved dosing:
- 1.75 mg subcutaneous injection 45 minutes before anticipated sexual activity
- Maximum: 1 dose per 24 hours; no more than 8 doses per month
- Route: Autoinjector pen into the abdomen or thigh
Off-Label Use in Men
While PT-141 is FDA-approved only for women, it is commonly used off-label in men for:
- Erectile dysfunction not responding well to PDE5 inhibitors
- Low libido regardless of testosterone levels
- Psychogenic ED where the issue is desire/arousal rather than vascular function
Research in men has shown PT-141 produces erections through a central mechanism, and several clinical studies demonstrated improved erectile function and sexual satisfaction in men with ED. Some men report it works well when PDE5 inhibitors are insufficient or cause unwanted vascular side effects.
Off-label dosing in men: typically 1–2 mg subcutaneous injection 45–90 minutes before activity.
Comparison to PDE5 Inhibitors (Viagra/Cialis)
| Feature | PT-141 | Sildenafil (Viagra) | Tadalafil (Cialis) | |---------|--------|--------------------|--------------------| | Mechanism | Central CNS (MC4R) | Peripheral (PDE5) | Peripheral (PDE5) | | Works on desire | Yes | No | No | | Works on physical arousal | Secondary | Primary | Primary | | Cardiovascular effects | Blood pressure decrease | Yes | Yes | | Duration of effect | 4–12 hours | 4–6 hours | Up to 36 hours | | Works without sexual stimuli | To some degree | No | No | | Approved for women | Yes | No (off-label only) | No |
Clinical Trial Results
In the RECONNECT Phase 3 trials:
- Approximately 25% of women receiving bremelanotide had a clinically meaningful improvement in satisfying sexual events vs. ~17% placebo
- Significant improvement in desire scores and reduction in distress
- Effects were maintained throughout the 52-week open-label extension
The effect size was described as modest by some reviewers — meaningful for those it works for, but not universally transformative.
Side Effects
Very Common (>20%):
- Nausea: The most common side effect, affecting approximately 40% of users. Usually peaks within 1 hour and resolves within a few hours. Premedication with ondansetron or antiemetics can reduce this significantly.
- Flushing: Facial and neck flushing, typically transient
Common (5–20%):
- Headache
- Blood pressure changes (transient decrease in blood pressure and increase in heart rate)
- Injection site reactions
- Hyperpigmentation (with repeated use, due to MC1R activity) — usually reversible
Less Common:
- Fatigue
- Nausea/vomiting severe enough to discontinue (reason for the 8-dose/month limit)
Important Contraindications:
- Cardiovascular disease or high risk (transient blood pressure decrease and heart rate increase are concerning in this population)
- Not for use with nitrates (as with PDE5 inhibitors)
- Not recommended during pregnancy
Managing Nausea
Nausea is the primary tolerability issue with PT-141. Strategies to reduce it:
- Ondansetron (Zofran) 4–8 mg taken 30 minutes before injection significantly reduces nausea for most users
- Smaller initial doses: Starting at 1 mg and titrating up allows tolerance assessment
- Eat beforehand: Some users find that having a small meal 1–2 hours before injection reduces GI distress
- Timing: Nausea typically peaks around 1 hour post-injection and resolves within 2–4 hours
Stacking PT-141
PT-141 is sometimes combined with:
- PDE5 inhibitors (low dose): The central desire mechanism of PT-141 combined with the peripheral vascular mechanism of sildenafil or tadalafil may produce synergistic effects in men with mixed-mechanism ED
- Kisspeptin: Kisspeptin has independent pro-sexual effects through GnRH stimulation; some combination protocols exist in research settings
Frequently Asked Questions
Q: How long does PT-141 take to work? Effects typically begin within 45–90 minutes of subcutaneous injection and can last 4–12 hours. The timing can vary based on individual metabolism and the specific activity of interest.
Q: Will PT-141 work if I have low testosterone? PT-141 works through a pathway largely independent of testosterone. It can be effective even in individuals with low testosterone, though addressing low T may further improve sexual function. The two interventions are complementary.
Q: Can PT-141 cause permanent hyperpigmentation? With repeated use, PT-141 can cause skin darkening, particularly in areas prone to pigmentation (moles, freckles, skin folds). This is typically reversible upon discontinuation, but the monthly dose limit in the Vyleesi label partly addresses this concern.
Q: Is PT-141 addictive? No evidence of addiction or dependence has been established. The melanocortin system is not considered addictive in the traditional sense, unlike opioid or dopaminergic systems directly.
Q: Can PT-141 be used by postmenopausal women? The FDA approval is specifically for premenopausal women. Off-label use in postmenopausal women has been reported, but efficacy data in this population is limited. Hormonal changes in menopause may affect the melanocortin system's responsiveness.
Recommended Products
Quality supplements mentioned in this article
Affiliate disclosure: We may earn a commission from purchases made through these links at no extra cost to you. This helps support our research.
Related Articles
More evidence-based reading
30-Day Peptide Challenge: Beginner Protocol, Daily Tracking, and Expected Milestones
A structured 30-day beginner peptide challenge with daily tracking templates, week-by-week milestones, and guidance on when to adjust your protocol.
7 min read →Peptides90-Day Peptide Transformation Protocol: Phased Approach for Body Composition and Energy
A phased 90-day peptide transformation protocol covering body composition, energy, sleep optimization, and blood work checkpoints for measurable results.
8 min read →PeptidesAnnual Peptide Cycling Plan: Quarterly Rotation, Seasonal Adjustments, and Budget Planning
A complete annual peptide cycling plan with quarterly rotations, seasonal protocol adjustments, blood work schedule, and practical budget planning for year-round use.
9 min read →